74 results about "Streptococcus agalactiae" patented technology

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

The invention discloses a zanthoxylum bungeanum leaf extract and a preparation method and application thereof.The preparation method includes the steps that zanthoxylum bungeanum leaves are cleaned, dried and then smashed, and zanthoxylum bungeanum leaf powder is obtained; condensing and extracting: taking the bunge pricklyash leaf powder, adding a solvent, heating, condensing and refluxing for a certain time, carrying out suction filtration after condensing and refluxing, collecting filtrate, repeatedly extracting for 2-5 times, adding the same volume of solvent each time, and combining the filtrate to obtain an extract; performing rotary evaporation: performing rotary evaporation on the extracting solution to obtain a concentrated solution; and drying: drying the concentrated solution, and grinding the dried concentrated solution into powder to obtain the bunge pricklyash leaf extract. The zanthoxylum bungeanum leaf extract prepared by the preparation method disclosed by the invention has an inhibiting effect on listeria monocytogenes, staphylococcus aureus, streptococcus agalactiae and bacillus cereus, provides a new way for preparing bacteriostatic products such as bacteriostatic drugs, bacteriostatic cleaning supplies and bacteriostatic feed additives, and is beneficial to development and utilization of zanthoxylum bungeanum leaf resources; the use value of bunge pricklyash leaves is improved, and resource waste is reduced.

The invention relates to the technical field of biology, in particular to a tilapia mossambica streptococcus agalactiae resistance related KASP molecular marker and application thereof. According to the invention, two SNP (Single Nucleotide Polymorphism) loci, namely SNP-1 and SNP-2, which are remarkably associated with resistance are screened based on an intron region of an EGFRX2 gene of tilapia mossambica, a typing method of the loci is developed through a KASP technology, and relevance between the genotype of the SNP-1 and a resistance phenotype is verified. Furthermore, streptococcus agalactiae resistance dominant diplotype individuals are screened in combination with double SNP loci, and the survival rate of a challenge experiment is remarkably improved. The detection kit provided by the invention can realize high-throughput and high-precision typing, is suitable for tilapia mossambica resistance genotype identification and molecular marker-assisted breeding, provides an efficient genetic improvement tool for tilapia mossambica disease-resistant breeding, and is beneficial to reduction of breeding disease loss and reduction of antibiotic dependence.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The application discloses a kind of fluorescence colorimetric double-mode detection streptococcus agalactiae without aerosol pollution method, comprising the following steps: (1) strain culture and DNA extraction;(2) the combination of UDG and LAMP;(3) UDG-LAMP-CRISPR fluorescence mode detection system;(4) colorimetric mode detection system: read image RGB value in G value, G value significantly increases, and it is positive result.This patent innovatively combines UDG, LAMP, CRISPR and G4, introduces connection probe to realize "fluorescence-colorimetric" single system double-mode detection.The two detection modes of the detection platform can be freely split or combined, and can meet the needs of different detection environments.By combining UDG system and LAMP technology, aerosol pollution possibly carried in amplification process is avoided.Connection probe is introduced, CRISPR fluorescence detection is combined with G4 colorimetric detection, a detection system with "fluorescence-colorimetric" two detection modes is established, which is used for quantitative identification and cross verification of streptococcus agalactiae.

The present invention relates to an immunogenic polysaccharide-protein conjugate comprising a capsular polysaccharide (CP) from Streptococcus agalactiae (commonly known as group B streptococcus (GBS)) and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the sialic acid level of the CP is higher than about 60%. The present invention also relates to methods of making the conjugate and immunogenic compositions comprising the conjugate. The present invention also relates to an immunogenic composition comprising a polysaccharide-protein conjugate, wherein the conjugate comprises CP from GBS serotype IV and at least one additional serotype. The present invention further relates to methods of using the compositions disclosed herein to induce an immune response against GBS in a subject and / or to reduce or prevent invasive GBS disease in a subject. The antibodies generated can be used for the treatment or prevention of GBS infection by passive immunotherapy.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The present application relates to the field of microbial technology, in particular to bacillus subtilis BS-1 and its application in water buffalo silage feed, the strain BS-1 of the present application has good bacteriostatic activity on escherichia coli, salmonella and streptococcus uberis, after mixing and fermenting according to a specific proportion with orange peel and cassava residue, the bacteriostatic spectrum of the obtained silage feed is significantly enhanced, which can simultaneously inhibit escherichia coli, campylobacter jejuni, salmonella, streptococcus uberis, staphylococcus aureus and streptococcus agalactiae that cause diarrhea and mastitis. In the feed, after mixing 60%-75% of orange peel and 25%-40% of cassava residue, the crude protein content of the fermentation product is significantly improved, and the fiber content is reduced. Feeding test shows that the feed can significantly improve the milk yield and milk quality of lactating water buffalo, and effectively alleviate diarrhea. The present application provides a safe, efficient and nutritious silage feed with disease prevention function.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

The present application relates to the field of aquaculture technology, in particular to a tilapia nilotica ferritin, a preparation method and application thereof, and a bacteriostatic agent.The amino acid sequence of the tilapia nilotica ferritin is shown as SEQ ID No.1, and the tilapia nilotica ferritin can inhibit Streptococcus agalactiae and / or Aeromonas hydrophila.The present application provides the tilapia nilotica ferritin, and in-vitro experiments have proved that the recombinant protein can effectively inhibit the proliferation of pathogenic bacteria.Further in-vivo experimental results show that the ferritin heavy chain (tilapia nilotica ferritin) has the important functions of inhibiting the proliferation of pathogenic bacteria and improving the survival rate of the organism, and plays an important role in the immune protection of the organism.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

The present invention discloses a method for preparing a eukaryotic expression vector of Nile tilapia CD36 protein and its application. The method comprises extracting RNA from Nile tilapia intestinal tissue and synthesizing cDNA; performing PCR amplification on the coding sequence fragment of the Nile tilapia CD36 gene to obtain the Nile tilapia CD36 protein gene; and then constructing a eukaryotic expression vector pEGFP-N1-CD36 of the Nile tilapia CD36 protein. The eukaryotic expression vector of the nucleotide sequence of the Nile tilapia CD36 protein prepared by the present invention can be used to prepare a product that improves the anti-streptococcal immunity of tilapia. The preparation of the product is simple, easy to operate, and low in cost. The present invention enhances the anti-streptococcal ability of tilapia by overexpressing the Nile tilapia CD36 protein in tilapia, thereby increasing the survival rate of tilapia infected with Streptococcus agalactiae by 60%. In addition, overexpressing the Nile tilapia CD36 protein in tilapia can also reduce the Streptococcus agalactiae load in tilapia. Therefore, it can be seen that the technical solution of the present invention can effectively induce cellular immunity in tilapia.

The invention discloses a Basa fish Mob1b antibacterial peptide as well as a coding sequence, application and a preparation method thereof, an antibacterial peptide precursor gene sequence is screened and identified from a Basa fish multi-omics data set based on a multi-omics method and biological big data, and an amino acid sequence of the Basa fish Mob1b antibacterial peptide as shown in SEQ ID NO: 3 is obtained through translation design; activity simulation prediction and in-vitro experiments prove that the Basa fish Mob1b antibacterial peptide has an inhibition effect on growth activity of streptococcus agalactiae, salmonella enteritidis, staphylococcus aureus, vibrio anguillarum and escherichia coli; the compound can be used for preparing various antibacterial agents, especially gram-positive bacteria streptococcus agalactiae, gram-negative escherichia coli staphylococcus aureus and vibrio anguillarum, can show an antibacterial effect when the concentration is 2.5 mu mol / L, can achieve the best antibacterial effect when the concentration is 5 mu mol / L, can be used for preparing various antibacterial agents and the like, and has good practical value and social and ecological benefits.

The invention provides a tilapia mossambica antibacterial peptide OnLEAP-2 and application thereof, an antibacterial peptide named OnLEAP-2 is cloned from tilapia mossambica, and a large number of antibacterial peptides are obtained through prokaryotic expression. The antibacterial peptide has a very good function of resisting streptococcus agalactiae, so that the survival rate of tilapia mossambica is remarkably increased, and pathogens are efficiently removed. The composition is suitable for bacterial disease control of economic fishes such as tilapia.

The present invention relates to molecular biology and aquaculture breeding, specifically to a method for obtaining a PRMT2 gene mutant by knocking out the gene based on CRISPR / Cas9 technology, and establishing an antibacterial strain of tilapia with a PRMT2 knockout. By knocking out this gene, a tilapia strain resistant to Streptococcus agalactiae can be obtained. Infection experiments revealed that tilapia with a PRMT2 knockout gene exhibited enhanced antibacterial activity compared to wild-type tilapia. This invention provides an important model for disease-resistant tilapia breeding and offers gene targets and new research directions for creating more disease-resistant fish strains and varieties.

The present invention relates to compositions and methods for detecting group B streptococcus (GBS, Streptococcus agalactiae) and identifying the most common genes responsible for clindamycin resistant GBS, such as ermB, ermTR, ermT, lsaC and lsaE, by multiplex real-time PCR assays.

The invention discloses a condom added with sophocarpidine hyaluronic acid lubricating liquid and a preparation method of the condom, and belongs to the technical field of condom production. The core of the method is that after matrine is dissolved, the matrine is added into hyaluronic acid lubricating liquid for the condoms, the hyaluronic acid lubricating liquid containing the matrine is prepared through stirring and mixing, the concentration of the matrine in the hyaluronic acid lubricating liquid is 7.7-25.0 mg / g, when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms, and when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms. And preparing the condom added with the sophocarpidine-containing hyaluronic acid lubricating liquid. According to the condom, inflammation generated after vaginal epithelial cells are stimulated by bacterial structural components is improved through matrine, and the common pathogenic bacteria such as staphylococcus aureus, escherichia coli, enterococcus faecalis and streptococcus agalactiae of vaginitis are inhibited in the using process; and the up-regulation level of NF-kB phosphorylation generated after lipopolysaccharide and peptidoglycan stimulate vaginal epithelial cells is relieved.